MX393395B - Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo. - Google Patents

Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo.

Info

Publication number
MX393395B
MX393395B MX2019010354A MX2019010354A MX393395B MX 393395 B MX393395 B MX 393395B MX 2019010354 A MX2019010354 A MX 2019010354A MX 2019010354 A MX2019010354 A MX 2019010354A MX 393395 B MX393395 B MX 393395B
Authority
MX
Mexico
Prior art keywords
preparation
amine derivative
sub
heteroaryl
medical uses
Prior art date
Application number
MX2019010354A
Other languages
English (en)
Other versions
MX2019010354A (es
Inventor
Biao Lu
Feng He
Shenglan Wang
Weikang Tao
Xiaodong Shen
Original Assignee
Jiangsu Hengrui Medicine Co
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Shanghai hengrui pharmaceutical co ltd filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2019010354A publication Critical patent/MX2019010354A/es
Publication of MX393395B publication Critical patent/MX393395B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Un derivado de heteroaril[4,3-c]pirimidin-5-amina, un método de preparación del mismo y usos médicos del mismo. Específicamente, un derivado de heteroaril[4,3-c]pirimidin-5-amina representado por una fórmula general (I), un método de preparación del mismo, una composición farmacéutica que contiene el derivado y usos del mismo como agentes terapéuticos, en particular, un uso como un antagonista del receptor A2a y un uso en la preparación de un medicamento para el tratamiento de afecciones o síntomas que se mejoran al inhibir el receptor A2a ; varios grupos sustituyentes en la fórmula general (I) tienen los significados idénticos a los de la especificación. (ver fórmula)
MX2019010354A 2017-03-16 2018-03-15 Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo. MX393395B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710156742 2017-03-16
CN201710982734 2017-10-20
PCT/CN2018/079086 WO2018166493A1 (zh) 2017-03-16 2018-03-15 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
MX2019010354A MX2019010354A (es) 2019-10-22
MX393395B true MX393395B (es) 2025-03-24

Family

ID=63523780

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010354A MX393395B (es) 2017-03-16 2018-03-15 Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo.

Country Status (13)

Country Link
US (1) US11312705B2 (es)
EP (1) EP3575301A4 (es)
JP (1) JP7111733B2 (es)
KR (1) KR20190129851A (es)
CN (1) CN109963854B (es)
AU (1) AU2018233367B2 (es)
BR (1) BR112019017108A2 (es)
CA (1) CA3054976A1 (es)
MX (1) MX393395B (es)
RU (1) RU2764655C2 (es)
TW (1) TWI772386B (es)
UA (1) UA125592C2 (es)
WO (1) WO2018166493A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015123424A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
LT3105218T (lt) 2014-02-13 2019-12-10 Incyte Corp Ciklopropilaminai kaip lsd1 inhibitoriai
WO2016007731A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines and imidazopyrazines as lsd1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
EA201792205A1 (ru) 2015-04-03 2018-02-28 Инсайт Корпорейшн Гетероциклические соединения как ингибиторы lsd1
DK3334709T3 (da) 2015-08-12 2025-02-03 Incyte Holdings Corp Salte af en lsd1-hæmmer
CN109535161B (zh) * 2017-09-22 2021-09-03 江苏恒瑞医药股份有限公司 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用
AU2019227607C1 (en) * 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors
EP3810610A1 (en) 2018-05-18 2021-04-28 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
CN117304191A (zh) 2018-07-05 2023-12-29 因赛特公司 作为a2a/a2b抑制剂的稠合吡嗪衍生物
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
AR116315A1 (es) * 2018-09-12 2021-04-21 Dizal Jiangsu Pharmaceutical Co Ltd Compuestos de triazolo-pirimidina y usos de los mismos
WO2020052648A1 (zh) * 2018-09-14 2020-03-19 江苏恒瑞医药股份有限公司 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的晶型及制备方法
CN110903291B (zh) * 2018-09-14 2021-09-03 江苏恒瑞医药股份有限公司 一种杂芳基并[4,3-c]嘧啶-5-胺类衍生物的盐、盐的晶型及制备方法
AR117164A1 (es) 2018-11-30 2021-07-14 Merck Sharp & Dohme Derivados de amino-triazoloquinazolina 9-sustituidos como antagonistas del receptor de adenosina, composiciones farmacéuticas y su uso para el tratamiento de diversos tipos de cáncer
JP7414827B2 (ja) 2018-12-20 2024-01-16 インサイト・コーポレイション アクチビン受容体様キナーゼ-2の阻害剤としてのイミダゾピリダジン及びイミダゾピリジン化合物
WO2020128036A1 (en) * 2018-12-21 2020-06-25 Ryvu Therapeutics S.A. Modulators of the adenosine a2a receptor
WO2020146795A1 (en) 2019-01-11 2020-07-16 Omeros Corporation Methods and compositions for treating cancer
TWI829857B (zh) * 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
CN111848625B (zh) * 2019-04-24 2022-07-26 江苏恒瑞医药股份有限公司 一种杂芳基并[4,3-c]嘧啶-5-胺类化合物的制备方法及中间体
WO2021156439A1 (en) 2020-02-06 2021-08-12 Astrazeneca Ab Triazole compounds as adenosine receptor antagonists
US12552799B2 (en) 2020-03-26 2026-02-17 Nxera Pharma Uk Limited Triazolone compounds
WO2021191376A1 (en) * 2020-03-26 2021-09-30 Astrazeneca Ab Triazolone compounds
CA3177056A1 (en) * 2020-03-26 2021-09-30 Astrazeneca Ab 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer
WO2021191378A1 (en) * 2020-03-26 2021-09-30 Astrazeneca Ab 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042711A1 (en) * 1997-03-24 1998-10-01 Kyowa Hakko Kogyo Co., Ltd. [1,2,4]TRIAZOLO[1,5-c]PYRIMIDINE DERIVATIVES
KR20010087361A (ko) * 1998-09-22 2001-09-15 히라타 다다시 [1,2,4]트리아졸로[1,5-c]피리미딘 유도체
US6355653B1 (en) * 1999-09-06 2002-03-12 Hoffmann-La Roche Inc. Amino-triazolopyridine derivatives
JP2002037787A (ja) * 2000-05-16 2002-02-06 Kyowa Hakko Kogyo Co Ltd [1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体の製造法
JPWO2003068776A1 (ja) 2002-02-15 2005-06-02 協和醗酵工業株式会社 [1,2,4]トリアゾロ[1,5−c]ピリミジン誘導体
PT1863818E (pt) * 2005-03-23 2010-04-09 Hoffmann La Roche Derivados de acetilenil-pirazolo-pirimidina como antagonistas de mglur2
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
DE102006008880A1 (de) 2006-02-27 2007-09-06 Merck Patent Gmbh Aminopyrimidinderivate
WO2007116106A1 (es) 2006-04-12 2007-10-18 Palobiofarma, S.L. Nuevos compuestos como antagonistas de los receptores a1 de adenosina
DE102007061763A1 (de) 2007-12-20 2009-06-25 Bayer Healthcare Ag Substituierte azabicyclische Verbindungen und ihre Verwendung
JP2011513417A (ja) 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンA2a受容体アンタゴニストとして使用するための1,2,4−トリアゾロ[4,3−c]ピリミジン−3−オンおよびピラゾロ[4,3−e]−1,2,4−トリアゾロ[4,3−c]ピリミジン−3−オン化合物
US8796297B2 (en) 2009-06-30 2014-08-05 Abbvie Inc. 4-substituted-2-amino-pyrimidine derivatives
JO3090B1 (ar) 2009-12-11 2017-03-15 Janssen Sciences Ireland Uc 5- امينو-4- هيدروكسي-بنتويل اميدات
ES2579949T3 (es) 2010-02-05 2016-08-17 Heptares Therapeutics Limited Derivados de 1,2,4-triazin-4-amina
JP5836367B2 (ja) 2010-05-12 2015-12-24 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated Atrキナーゼ阻害剤として有用な化合物
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
WO2011159302A1 (en) 2010-06-17 2011-12-22 Janssen Pharmaceutica Nv Arylindenopyrimidines for treating neurodegenerative and movement disorders while minimizing cardiac toxicity
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
CN103189377B (zh) 2010-10-29 2015-02-25 辉瑞大药厂 N1/n2-内酰胺乙酰辅酶a羧化酶抑制剂
US20140120087A1 (en) * 2011-04-21 2014-05-01 Bayer Intellectual Property Gmbh Triazolopyridines
TW201326170A (zh) * 2011-12-12 2013-07-01 拜耳製藥公司 經取代之三唑并吡啶
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
TWI628176B (zh) 2013-04-04 2018-07-01 奧利安公司 蛋白質激酶抑制劑
WO2015027431A1 (en) 2013-08-29 2015-03-05 Merck Sharp & Dohme Corp. 2,2-difluorodioxolo a2a receptor antagonists
ES2750791T3 (es) 2014-06-17 2020-03-27 Chiesi Farm Spa Derivados de indolizina como inhibidores de fosfoinositido 3-quinasas
MX375970B (es) * 2014-12-23 2025-03-06 Novartis Ag Compuestos de triazolopirimidina y usos de los mismos.
CN109535161B (zh) * 2017-09-22 2021-09-03 江苏恒瑞医药股份有限公司 三唑并嘧啶类衍生物、其制备方法及其在医药上的应用
AU2019227607C1 (en) * 2018-02-27 2023-07-20 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as A2A / A2B inhibitors

Also Published As

Publication number Publication date
JP2020510012A (ja) 2020-04-02
TWI772386B (zh) 2022-08-01
JP7111733B2 (ja) 2022-08-02
EP3575301A4 (en) 2020-08-05
RU2019131111A (ru) 2021-04-16
US11312705B2 (en) 2022-04-26
AU2018233367A1 (en) 2019-08-29
RU2019131111A3 (es) 2021-04-16
AU2018233367B2 (en) 2021-08-12
CA3054976A1 (en) 2018-09-20
TW201835083A (zh) 2018-10-01
EP3575301A1 (en) 2019-12-04
MX2019010354A (es) 2019-10-22
KR20190129851A (ko) 2019-11-20
RU2764655C2 (ru) 2022-01-19
US20210032224A1 (en) 2021-02-04
UA125592C2 (uk) 2022-04-27
CN109963854A (zh) 2019-07-02
CN109963854B (zh) 2022-04-12
BR112019017108A2 (pt) 2020-04-07
WO2018166493A1 (zh) 2018-09-20

Similar Documents

Publication Publication Date Title
MX2019010354A (es) Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo.
ZA202500997B (en) Benzoxazepin oxazolidinone compounds and methods of use
PH12020551870A1 (en) Tetracyclic heteroaryl compounds
SA518392101B1 (ar) ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ
EA201691151A1 (ru) Соединения для лечения пациентов с ros1-мутантными раковыми клетками
MX374346B (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
NZ708593A (en) Novel pyrazole derivative
PH12014502040A1 (en) Heterocyclyl compounds
MX2016009403A (es) Compuestos heterociclicos.
CR9304A (es) Antagonistas del receptor de glucagon, preparaciones y usos terapeuticos
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
MY208400A (en) Benzimidazole derivatives as modulators of retinoid-related orphan receptor gamma (ror) and pharmaceutical uses thereof
MX389592B (es) Moduladores alostericos positivos del receptor m1 muscarinico
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
GB201302704D0 (en) Therapeutic compounds
MX387785B (es) Compuestos heteroarilo y su uso como farmacos terapeuticos.
EA201492097A1 (ru) 5-амино[1,4]тиазины в качестве ингибиторов бета-секретазы 1
MX2018001945A (es) Fenoxiacetamidas apareadas novedosas.
EP4494705A3 (en) Non-peptide oxytocin receptor agonists
MX2017008495A (es) Nuevos derivados de bencimidazol como agentes antihistaminicos.
SA521421098B1 (ar) -h4 مركبات بيريدو بيريميدينات كمثبطات مستقبل هستامين
EA201792170A1 (ru) Производные индола
MX2019007360A (es) Derivado de triazol azabiciclo-sustituido, preparacion, metodo del mismo, y aplicacion de la misma en medicina.
TN2018000175A1 (en) Indane derivatives as mglur7 modulators